Durham, NC, United States
Durham, NC, United States

Duke University is a private research university located in Durham, North Carolina, United States. Founded by Methodists and Quakers in the present-day town of Trinity in 1838, the school moved to Durham in 1892. In 1924, tobacco and electric power industrialist James B. Duke established The Duke Endowment, at which time the institution changed its name to honor his deceased father, Washington Duke.The university's campus spans over 8,600 acres on three contiguous campuses in Durham as well as a marine lab in Beaufort. Duke's main campus—designed largely by African American architect Julian Abele—incorporates Gothic architecture with the 210-foot Duke Chapel at the campus' center and highest point of elevation. The first-year-populated East Campus contains Georgian-style architecture, while the main Gothic-style West Campus 1.5 miles away is adjacent to the Medical Center.Duke's research expenditures in the 2012 fiscal year were $1.01 billion, the seventh largest in the nation. Competing in the Atlantic Coast Conference, Duke's athletic teams, known as the Blue Devils, have captured 15 team national championships, including four by its high profile men's basketball team. Duke was ranked among the world's best universities by both THE and QS, while tying for 8th in the 2015 U.S. News & World Report "Best National Universities Rankings." In 2014, Thomson Reuters named 32 Duke professors to its list of Highly Cited Researchers. The only schools with more primary affiliations were Harvard, Stanford, and UC Berkeley. Wikipedia.


Time filter

Source Type

Patent
Georgetown University and Duke University | Date: 2016-04-05

Disclosed are heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. The compounds are useful for treating a mammal suffering from any one of a range of therapeutic indications, including Alzheimers disease, Parkinsons disease, dyskinesias, Tourettes syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Gansers syndrome, migraine pain, bulimia, obesity, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, disorders of sleep, autism, mutism, trichotillomania, and hypothermia.


Patent
Duke University | Date: 2016-05-13

The present invention generally relates to methods of modulating Ca_(v)1.2 channels and Ca_(v)1.2 channel activators.


Patent
Duke University | Date: 2016-06-17

Provided herein are compounds, compositions, including pharmaceutical compositions, having anti-cancer activity. Also provided are methods for diagnosing, detecting, and treating cancer in a subject, as well as a method for evaluating cancer stage in a subject, wherein the methods include determining the amount of a Ca^(2+)/calmodulin dependent kinase kinase (CaMKK) in a sample. Further provided are methods of screening and identifying a compound that inhibits CaMKK.


Patent
Duke University | Date: 2016-07-13

The present invention provides monoclonal antibodies and antigen-binding fragments thereof that specifically bind to CD20, as well as pharmaceutical compositions comprising the same. The invention further provides methods of using the monoclonal antibodies, antigen-binding fragments, and pharmaceutical compositions, for example, in methods of depleting B cells or in treating B cell disorders. Also provided are cells, nucleic acids and methods for producing the monoclonal antibodies.


Patent
Immunolight Llc. and Duke University | Date: 2016-08-25

Products, compositions, systems, and methods for modifying a target structure which mediates or is associated with a biological activity, including treatment of conditions, disorders, or diseases mediated by or associated with a target structure, such as a virus, cell, subcellular structure or extracellular structure. The methods may be performed in situ in a non-invasive manner by placing a nanoparticle having a metallic shell on at least a fraction of a surface in a vicinity of a target structure in a subject and applying an initiation energy to a subject thus producing an effect on or change to the target structure directly or via a modulation agent. The nanoparticle is configured, upon exposure to a first wavelength _(1), to generate a second wavelength _(2 )of radiation having a higher energy than the first wavelength _(1). The methods may further be performed by application of an initiation energy to a subject in situ to activate a pharmaceutical agent directly or via an energy modulation agent, optionally in the presence of one or more plasmonics active agents, thus producing an effect on or change to the target structure. Kits containing products or compositions formulated or configured and systems for use in practicing these methods.


Patent
Advanced Liquid Logic, Inc. and Duke University | Date: 2016-12-01

Methods and devices for conducting chemical or biochemical reactions that require multiple reaction temperatures are described. The methods involve moving one or more reaction droplets or reaction volumes through various reaction zones having different temperatures on a microfluidics apparatus. The devices comprise a microfluidics apparatus comprising appropriate actuators capable of moving reaction droplets or reaction volumes through the various reaction zones.


Patent
Johns Hopkins University and Duke University | Date: 2016-11-16

We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in glioblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.


Patent
Duke University and The Government Of The United States As Represented By The Secretary Of Health And Human Services | Date: 2016-10-11

We tested the in vitro and in vivo efficacy of a recombinant bispecific immunotoxin that recognizes both EGFRwt and tumor-specific EGFRvIII receptors. A single chain antibody was cloned from a hybridoma and fused to toxin, carrying a C-terminal peptide which increases retention within cells. The binding affinity and specificity of the recombinant bispecific immunotoxin for the EGFRwt and the EGFRvIII proteins was measured. In vitro cytotoxicity was measured. In vivo activity of the recombinant bispecific immunotoxin was evaluated in subcutaneous models and compared to that of an established monospecific immunotoxin. In our preclinical studies, the bispecific recombinant immunotoxin, exhibited significant potential for treating brain tumors.


Patent
Duke University | Date: 2016-11-14

Optical systems based on an objective lens comprising one or more plastic lens elements are disclosed. The inclusion of plastic lens element reduces one or more of system cost, size, weight, and/or complexity. The chromatic performance of some imaging systems in accordance with the present invention is improved by incorporation of a diffractive surface into the entry surface of the objective lens.


Patent
Duke University | Date: 2017-04-19

The present invention relates to compositions, methods, and kits for eliciting an immune response to at least one CMV antigen expressed by a cancer cell, in particular for treating and preventing cancer. CMV determination methods, compositions, and kits also are provided.

Loading Duke University collaborators
Loading Duke University collaborators